دورية أكاديمية
أعرض في EDS

Combined Therapy Using Human Corneal Stromal Stem Cells and Quiescent Keratocytes to Prevent Corneal Scarring after Injury.

التفاصيل البيبلوغرافية
العنوان: Combined Therapy Using Human Corneal Stromal Stem Cells and Quiescent Keratocytes to Prevent Corneal Scarring after Injury.
المؤلفون: Jhanji V; Corneal Regeneration Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA., Santra M; Corneal Regeneration Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA., Riau AK; Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore 169856, Singapore.; Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore 169857, Singapore., Geary ML; Corneal Regeneration Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA., Yang T; Corneal Regeneration Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA., Rubin E; Corneal Regeneration Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA., Yusoff NZBM; Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore 169856, Singapore., Dhaliwal DK; Corneal Regeneration Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA., Mehta JS; Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore 169856, Singapore.; Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore 169857, Singapore., Yam GH; Corneal Regeneration Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA.; Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore 169856, Singapore.; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Jun 23; Vol. 23 (13). Date of Electronic Publication: 2022 Jun 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Cicatrix*/metabolism , Cicatrix*/prevention & control , Corneal Injuries*/metabolism, Animals ; Cornea/metabolism ; Corneal Stroma ; Fibrosis ; Humans ; Mice ; Stem Cells/metabolism
مستخلص: Corneal blindness due to scarring is conventionally treated by corneal transplantation, but the shortage of donor materials has been a major issue affecting the global success of treatment. Pre-clinical and clinical studies have shown that cell-based therapies using either corneal stromal stem cells (CSSC) or corneal stromal keratocytes (CSK) suppress corneal scarring at lower levels. Further treatments or strategies are required to improve the treatment efficacy. This study examined a combined cell-based treatment using CSSC and CSK in a mouse model of anterior stromal injury. We hypothesize that the immuno-regulatory nature of CSSC is effective to control tissue inflammation and delay the onset of fibrosis, and a subsequent intrastromal CSK treatment deposited collagens and stromal specific proteoglycans to recover a native stromal matrix. Using optimized cell doses, our results showed that the effect of CSSC treatment for suppressing corneal opacities was augmented by an additional intrastromal CSK injection, resulting in better corneal clarity. These in vivo effects were substantiated by a further downregulated expression of stromal fibrosis genes and the restoration of stromal fibrillar organization and regularity. Hence, a combined treatment of CSSC and CSK could achieve a higher clinical efficacy and restore corneal transparency, when compared to a single CSSC treatment.
References: JAMA Ophthalmol. 2016 Feb;134(2):167-73. (PMID: 26633035)
Vision (Basel). 2021 Sep 22;5(4):. (PMID: 34698278)
Front Med (Lausanne). 2021 Feb 23;8:650724. (PMID: 33708786)
Stem Cells. 2009 Jul;27(7):1635-42. (PMID: 19544455)
Cells. 2022 Jan 05;11(1):. (PMID: 35011740)
Regen Med. 2016 Sep;11(6):601-15. (PMID: 27498943)
Stem Cells. 2005 Oct;23(9):1266-75. (PMID: 16051989)
Int J Mol Sci. 2017 Jun 12;18(6):. (PMID: 28604651)
Eye Vis (Lond). 2019 Oct 12;6:30. (PMID: 31632999)
J Adv Res. 2022 May 25;:. (PMID: 35623612)
Int J Burns Trauma. 2012;2(1):18-28. (PMID: 22928164)
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1382-8. (PMID: 19875671)
Exp Eye Res. 2007 Sep;85(3):305-11. (PMID: 17655845)
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4044-4053. (PMID: 30098200)
Front Microbiol. 2017 Mar 28;8:538. (PMID: 28400769)
Sci Rep. 2015 Mar 04;5:8733. (PMID: 25736434)
Sci Transl Med. 2014 Dec 10;6(266):266ra172. (PMID: 25504883)
Sci Rep. 2016 May 19;6:26227. (PMID: 27195722)
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):241-8. (PMID: 16384969)
Invest Ophthalmol Vis Sci. 2000 Jan;41(1):96-102. (PMID: 10634607)
Eye Vis (Lond). 2020 Nov 3;7(1):52. (PMID: 33292650)
Exp Eye Res. 2020 Nov;200:108270. (PMID: 32979396)
Cornea. 2005 Nov;24(8 Suppl):S2-S11. (PMID: 16227819)
Prog Retin Eye Res. 2004 Jul;23(4):403-34. (PMID: 15219875)
Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):28. (PMID: 32084275)
Sci Rep. 2017 Mar 28;7:45396. (PMID: 28349952)
Cell Transplant. 2015;24(9):1845-61. (PMID: 25291523)
Eye (Lond). 2020 Feb;34(2):271-278. (PMID: 31831879)
Int J Biochem Cell Biol. 2006;38(10):1625-31. (PMID: 16675284)
Int J Mol Sci. 2017 Aug 23;18(9):. (PMID: 28832498)
J Immunol. 2014 Mar 1;192(5):2177-85. (PMID: 24501198)
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3648-54. (PMID: 19264894)
Inflamm Regen. 2018 Oct 29;38:29. (PMID: 30397418)
Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2795-803. (PMID: 11687520)
J Neurosci Res. 2017 Sep;95(9):1712-1729. (PMID: 28489286)
Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1959-67. (PMID: 10440249)
PLoS One. 2017 Mar 3;12(3):e0171712. (PMID: 28257425)
Prog Retin Eye Res. 1999 Jul;18(4):529-51. (PMID: 10217482)
Invest Ophthalmol Vis Sci. 2001 Feb;42(2):333-9. (PMID: 11157863)
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3340-3354. (PMID: 30025076)
Methods Mol Biol. 2013;1014:45-52. (PMID: 23690003)
Transplantation. 2019 Dec;103(12):2468-2478. (PMID: 31765363)
Front Med (Lausanne). 2021 Apr 27;8:616200. (PMID: 33987189)
Br J Ophthalmol. 2015 Jul;99(7):878-87. (PMID: 25349081)
Am J Pathol. 2007 Jan;170(1):100-9. (PMID: 17200186)
Sci Rep. 2017 Oct 16;7(1):13267. (PMID: 29038497)
J Exp Med. 2013 Jul 1;210(7):1283-99. (PMID: 23825232)
Exp Eye Res. 2001 Jan;72(1):33-9. (PMID: 11133180)
Exp Eye Res. 2016 Jan;142:110-8. (PMID: 26675407)
Lancet. 2012 May 5;379(9827):1749-61. (PMID: 22559901)
Int J Ophthalmol. 2021 Mar 18;14(3):448-455. (PMID: 33747824)
Exp Eye Res. 2020 Jul;196:108062. (PMID: 32442558)
Am J Respir Crit Care Med. 2000 May;161(5):1698-704. (PMID: 10806177)
معلومات مُعتمدة: High Impact Research Grant 2021 Eye Bank Association of America; ITTC Immune Transplant and Therapy Centre University of Pittsburgh Medical Center; P30, EY008098 United States EY NEI NIH HHS
فهرسة مساهمة: Keywords: cell therapy; corneal scarring; corneal stromal keratocytes; corneal stromal stem cells; mouse corneal injury
تواريخ الأحداث: Date Created: 20220709 Date Completed: 20220712 Latest Revision: 20220716
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9267074
DOI: 10.3390/ijms23136980
PMID: 35805991
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms23136980